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The current SARS-CoV-2 pandemic is wreaking
havoc throughout the world and has rapidly become
a global health emergency. A central question con-
cerning COVID-19 is why some individuals become
sick and others not. Many have pointed already at
variation in risk factors between individuals. How-
ever, the variable outcome of SARS-CoV-2 infections
may, at least in part, be due also to differences
between the viral subspecies with which individuals
are infected. A more pertinent question is how we are
to overcome the current pandemic. A vaccine against
SARS-CoV-2 would offer significant relief, although
vaccine developers have warned that design, testing
and production of vaccines may take a year if not
longer. Vaccines are based on a handful of different
designs (i), but the earliest vaccines were based on
the live, attenuated virus. As has been the case for
other viruses during earlier pandemics, SARS-CoV-2
will mutate and may naturally attenuate over time (ii).
What makes the current pandemic unique is that,
thanks to state-of-the-art nucleic acid sequencing
technologies, we can follow in detail how SARS-
CoV-2 evolves while it spreads. We argue that knowl-
edge of naturally emerging attenuated SARS-CoV-2
variants across the globe should be of key interest in
our fight against the pandemic.
As expected for any RNA virus (Holmes, 2009; Grubaugh
et al., 2020), over time, individuals are infected with
SARS-CoV-2 variants that typically display some degree
of genetic drift, compared with the first isolates of the
virus obtained in Wuhan (Genomic epidemiology of
hCoV-19 available at https://www.gisaid.org/epiflu-
applications/next-hcov-19-app/). Indeed, this genetic drift
permits SARS-CoV-2 variants to be tracked as they
spread around the globe (Forster et al., 2020). We know
from studying viral evolution that genetic drift, in particular
derived from genomic deletions, will almost inevitably
attenuate the pathogenicity of viruses given enough time
(Holmes, 2009). It is entirely plausible that, at present, some
individuals, by chance, have already become infected with
attenuated versions of SARS-CoV-2. Since self-seclusion of
the symptomatic and those at high risk has been prompted
by many authorities, there may have been, concomitantly,
selective advantages for potential attenuated variants of
SARS-CoV-2 to spread over non-attenuated variants. Fortu-
nately, COVID-19-related hospitalizations and fatalities
have decreased several weeks after lock-down measures
were installed in various countries. Clearly, the reduction in
transmission of the non-attenuated virus has been key in
these successes. It cannot be excluded, however, that the
competition of attenuated strains with the non-attenuated
SARS-CoV-2 has also played a role in curbing demand on
the health care systems.
Reasoning along these lines, competition of attenuated
variants with the non-attenuated SARS-CoV-2 may
explain certain particularities in the course of the epi-
demic at different locations around the globe. Although
currently available data on mortality for the SARS-CoV-
2-caused pandemic [Novel Coronavirus (COVID-19)
Infection Map available at https://hgis.uw.edu/virus/]
should be interpreted with caution, it seems that case
fatality rates tail off even in locations with less effective
containment measures. Furthermore, the effects of foun-
der events may shed light on the atypical dynamics of
some local epidemics, which pair high numbers of infec-
tions with low mortality rates. For example, if many of the
first local spreaders of the virus were infected with attenu-
ated strains, the spread of the non-attenuated virus may
have been blunted from the onset, due to competition.
Mathematical modelling may provide support for these
hypotheses in further detail, in particular after more reli-
able data becomes accessible.
Currently available sequences for SARS-CoV-2 isolates
from across the globe confirm that genetic drift is occurring
(Grubaugh et al., 2020; Genomic epidemiology of hCoV-
19 available at https://www.gisaid.org/epiflu-applications/
next-hcov-19-app/), although the association between
these genetic alterations and severity of clinical outcome
are sparse. The only hint at attenuation comes from an
observation in Singapore, where some SARS-CoV-2 iso-
lates turned out to have a 382-nucleotide deletion in ORF8
of the viral genome (Su et al., in press). This finding is of
particular interest, because a deletion of 29 nucleotides
appeared in ORF8 during early spreading of SARS-CoV-1
in 2003. This 29 nucleotide deletion was demonstrated to
attenuate viral replication when introduced in an infectious
clone generated by reverse genetics (Muth et al., 2018).
Likewise, the SARS-Unique Domain in the Nsp3 protein of
SARS-CoV-1, which is partially conserved in SARS-
Cov-2, has been linked to evasion of host immune recog-
nition, suggesting that the loss of this domain could result
in reduced virulence (Snijder et al., 2003; Ma-Laueret al.,
2016; Srinivasan et al., 2020). Based on these examples
and others (Benvenuto et al., n.d.), one would expect that
attenuated variants of SARS-CoV-2 would emerge as the
pandemic unfolds.
We argue that sequencing efforts, thus far, likely
underestimate the emergence of attenuated SARS-
CoV-2 variants. Most of the isolates that have been
analysed are derived from individuals that sought medical
care, and, hence, are unlikely to have acquired any fea-
tures leading to reduced virulence. Instead, currently
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existing attenuated SARS-CoV-2 variants should be
searched for in the large pool of infected individuals that
remain asymptomatic. An interesting aside from an evolu-
tionary perspective is that lock-down and other counter-
measures may have accelerated local enrichments of
particular SARS-CoV-2 variants. In any case, should par-
ticular viral variants be linked to various levels of virus
attenuation (or aggressiveness), such findings would
have implications for diagnostics, prognostics, disease
support management, and eventually, what type of pan-
demic management policies would be required.
With present-day sequencing prowess, it is feasible to
sequence hundreds of thousands of viral genomes,
starting from the raw material collected for diagnostic Q-
PCR testing. For this, worldwide sequencing platforms
could dedicate time and workhorse instruments for
sequencing virus-positive samples. We argue that given
testing capacity is expanding, it should extend also to
samples from asymptomatic individuals. Sample identifi-
cation of positively tested individuals would allow deter-
mination by follow-up of who was and remained
asymptomatic. All viral sequences at centralized
sequence repositories then should be annotated for
symptomatic or asymptomatic clinical outcomes and
other relevant medical parameters, such as age, gender
and comorbidities (in accordance with appropriate patient
privacy legislation). The next step would be to score for
specific genetic determinants of the virus, in particular
deletions, that are enriched within the pool of isolates
derived from confirmed asymptomatic populations but
absent in isolates from symptomatic COVID-19 patients.
The focus should be on those genetic determinants of
SARS-CoV-2 isolates that would correlate with asymptom-
atic outcomes and that would be spread at relatively high
frequencies. It is key that these potentially attenuated
sequences are also found in individuals who otherwise
would be at high-risk of developing severe symptoms from
COVID-19, such as 60+ year-old individuals with com-
orbidities that are considered to be risk factors. These indi-
viduals could then be approached to be tested for having
undergone seroconversion and, if so, for consistent and
prolonged asymptomatic status. Statistics should support
whether these individuals would be, at least for some time,
protected from reinfection with non-attenuated SARS-
CoV-2, with a confidence assessment at least comparable
with the current standard for phase III clinical trials con-
cerning a typical designer vaccine. In other words, the pan-
demic, itself, already may have inadvertently performed a
‘natural’ clinical trial, which, for regular vaccine develop-
ment, is by far the most time-consuming step.
On the whole, the current global crisis is of a magni-
tude such that it is feasible to identify currently existing
attenuated SARS-CoV-2 variants and to assess their
prevalence. Such an effort would be instrumental not only
to better understand the evolution of SARS-CoV-2 as it
spreads among humans but also to predict the dynamics
of the current and, possibly, also future pandemics
(Ng et al., 2003). Knowledge of SARS-CoV-2 attenuation
might also have relevance for developing safer and more
effective anti-SARS-CoV-2 vaccines. Live attenuated
anti-SARS-CoV-2 vaccines would entail some unknown
degree of risk and may cause unpredictable outcomes,
for instance, due to recombination events (Zhang et al.,
2019), in particular, if the non-attenuated virus would
remain widespread. Indeed, designer vaccines have rep-
laced live attenuated vaccines these days because of
safety concerns (Vaccine Types available at https://www.
vaccines.gov/basics/types). We, nevertheless, argue that
the determination of naturally circulating attenuated
SARS-CoV-2 variants is an urgent matter.
Note added in proof
An interesting study has come out in Medrxiv, supporting
the notion that there likely is a wide range in pathogenic-
ity of circulating SARS-CoV-2 variants, as reflected by
variable cytopathic effects and production levels of viral
progeny in Vero-E6 cells,depending on the SARS-CoV-2
variant these cells were infected with (Yao et al., 2020).
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